

Statement of Standalone Un-Audited Financial Results for the Quarter ended June 30, 2021

(Rs. In Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended
		30/06/2021	31/03/2021	30/06/2020	31/03/2021
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operations	837.28	1283.98	602.39	3693.30
II	Other Income	0.02	8.68	0.47	9.26
III	<b>Total Revenue (I + II)</b>	<b>837.29</b>	<b>1292.66</b>	<b>602.85</b>	<b>3702.56</b>
IV	Expenses :				
	(a) Cost of Materials Consumed	267.83	502.92	327.57	1581.21
	(b) Purchases of Stock-in-Trade	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	45.73	237.42	(273.21)	(544.79)
	(d) Employee Benefits Expense	245.23	252.97	224.07	997.98
	(e) Finance Costs	45.41	65.75	25.13	201.68
	(f) Depreciation and Amortisation Expense	36.54	36.96	38.36	155.08
	(g) Other Expenses	186.09	180.76	239.59	1158.41
	<b>Total expenses (IV)</b>	<b>826.83</b>	<b>1276.77</b>	<b>581.51</b>	<b>3549.57</b>
V	Profit / (Loss) before Exceptional items and Tax (III - IV)	10.46	15.88	21.34	152.99
VI	Exceptional Items	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	10.46	15.88	21.34	152.99
VIII	Tax Expense :				
	(1) Current Tax	2.91	19.49	5.55	54.00
	(2) Deferred tax	-	-	-	2.81
	<b>Total Tax Expenses</b>	<b>2.91</b>	<b>19.49</b>	<b>5.55</b>	<b>56.81</b>
IX	Profit / (Loss) for the period form Continuing Operations (VII -VIII)	7.55	(3.61)	15.79	96.18
X	Profit / (Loss) from Discontinued Operations	-	-	-	-
XI	Tax expenses of Discontinued Operations	-	-	-	-
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	7.55	(3.61)	15.79	96.18
XIV	Other Comprehensive Income				
	A. (I) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B. (I) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	7.55	(3.61)	15.79	96.18
XVI	Details of Equity share capital				
	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	364.83	364.83
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00
XVII	Earnings Per Equity Share (for Continuing operation) :				
	(a) Basic	0.21	(0.10)	0.43	2.64
	(b) Diluted	0.21	(0.10)	0.43	2.64
XVIII	Earnings Per equity share (for Discontinued operation) :				
	(a) Basic	-	-	-	-
	(b) Diluted	-	-	-	-
XIX	Earnings Per Equity Share (for Discontinued & Continuing operation) :				
	(a) Basic	0.21	(0.10)	0.43	2.64
	(b) Diluted	0.21	(0.10)	0.43	2.64

Notes:

- The Company has one reportable business segment "Medical Devices".
- The above Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2021 ("Statement") is prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 10th August, 2021. The Statement is subjected to 'limited review' by the Auditors of the Company and their report contains no qualification.
- In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a Limited Review of the Standalone Un-Audited Financial Results for the quarter ended June 30, 2021.

4). Impact of COVID-19 Pandemic

The COVID-19 outbreak has spread rapidly during the last financial year. Governments across the globe, including in India, have undertaken various measures to contain the spread of this virus including restrictions on travel, social distancing, and other emergency measures. These measures have had a direct impact on our business and have affected the supply chains and production of our medical devices. Lower economic activity has also resulted in the suppressed demand for our medical devices. Our Company experienced delays in delivery of supplies to hospitals and nursing homes due to restrictions on courier services. In view of the lockdown and curfew announced across many states in India, the Company has undertaken and strengthened various measures to ensure the safety and well-being of its employees and has focused on continued delivery of medical devices across the country, by ensuring that its key functions i.e. procurement, manufacturing, supply chain, marketing, sales and support functions continue to operate smoothly. Management has considered its liquidity position as at June 30, 2021 and over the next nine months from the date of approval of these financial statements, and has concluded that the Company may face liquidity in the course of business.

5). The unaudited results for the Quarter ended June 30, 2021 are available on the website of BSE Limited at [www.bseindia.com](http://www.bseindia.com) and on Company's website at [www.centennialindia.com](http://www.centennialindia.com).

for and on behalf of the Board of Directors of  
for CENTENIAL SURGICAL SUTURE LTD.



Place : Mumbai, Maharashtra  
Date : August 10, 2021

**Vijay MAJREKAR**  
Managing Director & Chief Executive Officer  
DIN : 00804808